Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04752696
Recruitment Status : Recruiting
First Posted : February 12, 2021
Last Update Posted : May 14, 2021
Sponsor:
Information provided by (Responsible Party):
Cardiff Oncology

Brief Summary:
The main objective of this trial is to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic pancreatic ductal adenocarcinoma (PDAC).

Condition or disease Intervention/treatment Phase
Pancreatic Ductal Adenocarcinoma Drug: Onvansertib Drug: Nanoliposomal irinotecan Drug: Leucovorin Drug: Fluorouracil Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Study of Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Actual Study Start Date : May 3, 2021
Estimated Primary Completion Date : February 13, 2023
Estimated Study Completion Date : March 11, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU
The first 3 participants will be administered onvansertib orally once a day at a dosing schedule of 12 mg/m^2 on Day 1 to Day 10 for two cycles, where each cycle is 2 weeks. Depending on the number of dose limiting toxicities (DLTs) experienced in the first 3 participants, additional participants may receive different dosing schedules, determining the dosing schedule to be used in the treatment period. Onvansertib will be administered in combination with 70 mg/m^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m^2 leucovorin and 2400 mg/m^2 fluorouracil (5-FU).
Drug: Onvansertib
Oral capsule
Other Name: PCM-075

Drug: Nanoliposomal irinotecan
Intravenous infusion
Other Names:
  • Onivyde
  • Nal-IRI

Drug: Leucovorin
Intravenous infusion

Drug: Fluorouracil
Intravenous infusion
Other Name: 5-FU

Experimental: Treatment Period: Onvansertib + nal-IRI + leucovorin + 5-FU
Participants will be administered onvansertib at the dosing schedule selected based on the results of the safety lead-in, in cycles of 2 weeks. Onvansertib will be administered in combination with 70 mg/m^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m^2 leucovorin and 2400 mg/m^2 fluorouracil (5-FU).
Drug: Onvansertib
Oral capsule
Other Name: PCM-075

Drug: Nanoliposomal irinotecan
Intravenous infusion
Other Names:
  • Onivyde
  • Nal-IRI

Drug: Leucovorin
Intravenous infusion

Drug: Fluorouracil
Intravenous infusion
Other Name: 5-FU




Primary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: 6 months ]

Secondary Outcome Measures :
  1. Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE) [ Time Frame: Up to 2 years ]
  2. Duration of Response (DOR) [ Time Frame: Up to 2 years ]
  3. Overall Response Rate (ORR) in Participants Who Receive At Least 2 Treatment Cycles [ Time Frame: Up to 2 years ]
    Each cycle is 2 weeks.

  4. Overall Survival (OS) [ Time Frame: Up to 2 years ]
  5. Disease Control Rate (DCR) [ Time Frame: Up to 2 years ]
  6. Reduction from Baseline in Serum CA19-9 Response [ Time Frame: Baseline up to 2 years ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically confirmed metastatic PDAC
  • Has received 1 prior gemcitabine-based chemotherapy as first line therapy for metastatic disease. Progression after completion of neoadjuvant or adjuvant therapy of < 6 months in duration is considered 1 line of therapy for metastatic disease
  • Has measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), defined as at least 1 lesion that can be accurately measured in at least 1 dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral computed tomography (CT) scan
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
  • Must be willing and able to undergo a tissue biopsy at screening; participants who, in the opinion of the investigator, do not have tissue that is accessible for biopsy are excepted from this criterion
  • Women of childbearing potential: (defined as not post-menopausal for 12 months or no previous surgical sterilization) and fertile men must agree to use adequate contraception for the duration of study participation and for 4 months after the last dose of nal-IRI. Male subjects must agree to refrain from sperm donation during the study and for 4 months after the last dose of nal-IRI
  • Ability to understand and the willingness to sign a written informed consent document. Signed informed consent form must be obtained prior to initiation of study evaluations and/or activities
  • International Normalized Ratio (INR) < 1.5 unless on warfarin
  • Participants with prior malignancy and who were treated with no evidence of active disease more than 2 years from initial diagnosis are eligible
  • Age ≥ 18 years
  • Participants must have adequate organ and bone marrow function

Exclusion Criteria:

  • Prior treatment with irinotecan, nal-IRI, or investigational PLK1 inhibitor
  • Uncontrolled intercurrent illness including symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, and myocardial infarction within 3 months of initiation of therapy
  • History of interstitial pneumonitis or interstitial lung disease
  • Participants with microsatellite instability-high (MSI-H) tumors with no prior immune checkpoint inhibitor exposure
  • Pregnancy or lactation
  • Participant has active and uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
  • QT interval with Fridericia's correction (QTcF) > 470 milliseconds. The QTcF should be calculated as the arithmetic mean of the QTcF on triplicate electrocardiograms (ECGs). In the case of potentially correctible causes of QT prolongation, (eg, medications, hypokalemia), the triplicate ECG may be repeated once during Screening and that result may be used to determine eligibility
  • Planned concomitant use of medications known to prolong the QT/QTc interval
  • Participant has undergone major surgical resection within 4 weeks prior to enrollment
  • Participant received radiotherapy, surgery, chemotherapy, or an investigational therapy within 2 weeks prior to study entry
  • Participant has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the participant to receive an experimental research drugs
  • Serious psychiatric or medical conditions that could interfere with treatment
  • Major bleeding in the last 4 weeks
  • More than 1 prior chemotherapy regimen administered in the metastatic setting
  • Unable or unwilling to swallow oral medication
  • Use of strong CYP3A4 or UGT1A1 inhibitors or strong CYP3A4 inducers. Participants currently receiving these agents who are able to switch to alternate therapy are not excluded. Inhibitors should be stopped at least one week prior to the first dose of protocol therapy and inducers should be stopped at least two weeks prior to initiation of protocol therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04752696


Contacts
Layout table for location contacts
Contact: Cardiff Oncology Please email info@cardiffoncology.com

Locations
Layout table for location information
United States, Arizona
Mayo Clinic Phoenix Recruiting
Phoenix, Arizona, United States, 85054
Contact: Clinical Trial Referral Office    855-776-0015      
United States, Florida
Mayo Clinic Jacksonville Recruiting
Jacksonville, Florida, United States, 32224
Contact: Clinical Trial Referral Office    855-776-0015      
United States, Kansas
University of Kansas Medical Center Not yet recruiting
Westwood, Kansas, United States, 66205
United States, Minnesota
Mayo Clinic Rochester Recruiting
Rochester, Minnesota, United States, 55905
Contact: Clinical Trials Referral Office    855-776-0015      
United States, Nebraska
University of Nebraska Medical Center Not yet recruiting
Omaha, Nebraska, United States, 68198
United States, Virginia
Inova Schar Cancer Institute Not yet recruiting
Fairfax, Virginia, United States, 22031
Sponsors and Collaborators
Cardiff Oncology
Layout table for additonal information
Responsible Party: Cardiff Oncology
ClinicalTrials.gov Identifier: NCT04752696    
Other Study ID Numbers: CRDF-001
First Posted: February 12, 2021    Key Record Dates
Last Update Posted: May 14, 2021
Last Verified: May 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Cardiff Oncology:
Pancreatic Ductal Adenocarcinoma
Onvansertib
Nanoliposomal irinotecan
Leucovorin
Fluorouracil
PLK1
PLK Inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Leucovorin
Fluorouracil
Irinotecan
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Antidotes
Protective Agents
Vitamin B Complex
Vitamins
Micronutrients
Nutrients
Growth Substances